Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 7/20 | 0.81 |
| ▸ | AURKA | O14965 | 4/20 | 0.77 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.66 |
| ▸ | EGFR | P00533 | 4/20 | 0.66 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.62 |
| ▸ | KDR | P35968 | 6/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2463942 | 0.99 | AURKB (0.80) | AURKBAURKAMAPK14EGFRIRAK4 | |
| SCHEMBL5649152 | 0.91 | AURKA (0.69) | AURKBAURKAMAPK14EGFRKDR | |
| SCHEMBL5652035 | 0.90 | AURKA (0.68) | AURKBAURKAMAPK14EGFRKDR | |
| SCHEMBL3531809 | 0.90 | AURKB (1.00) | AURKBAURKAMAPK14EGFRIRAK4 | |
| SCHEMBL5016550 | 0.90 | KDR (0.74) | AURKBAURKAMAPK14EGFRKDR | |
| SCHEMBL3527282 | 0.87 | AURKB (0.94) | AURKBAURKAMAPK14EGFRIRAK4 | |
| SCHEMBL10152557 | 0.87 | AURKA (0.69) | AURKBAURKAMAPK14EGFRIRAK4 | |
| Hydrochloric Acid SCHEMBL5652341 | 0.86 | AURKA (0.69) | AURKBAURKAMAPK14EGFRIRAK4 | |
| Hydrochloric Acid SCHEMBL2063014 | 0.86 | AURKA (0.69) | AURKBAURKAMAPK14EGFRIRAK4 | |
| Hydrochloric Acid SCHEMBL3531894 | 0.86 | AURKB (0.92) | AURKBAURKAMAPK14EGFRIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148531-B2 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2012-04-03 | — | — | US | disclosed |
| US-8148531-B2 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2012-04-03 | — | — | US | disclosed |
| EP-1877383-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2011-09-07 | — | — | EP | disclosed |
| US-20090131461-A1 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2009-05-21 | — | — | US | disclosed |
| US-20090131461-A1 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2009-05-21 | — | — | US | disclosed |
| US-7235559-B1 | Therapeutic quinazoline derivatives | ASTRAZENECA AB (SE) | 2007-06-26 | — | — | US | disclosed |
| EP-1218355-A1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001021597-A1 | THERAPEUTIC QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131461-A1 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CDK1, AURKC, CSNK1G3 | AURKB 19/4885AURKA 8/4885MAPK14 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.